The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure

European Journal of Heart Failure

Volumn 7, Issue 6, 2005, Pages 966-973

  De Groote, Pascal ^a   Lamblin, Nicolas ^a,b   Helbecque, Nicole ^b   Mouquet, Frédéric ^a   Mc Fadden, Eugène ^c   Hermant, Xavier ^b   Amouyel, Philippe ^b   Dallongeville, Jean ^b   Bauters, Christophe ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Genetics; Heart failure; Prognosis; Receptors adrenergic beta

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR DOWN REGULATION; STATISTICAL SIGNIFICANCE; SURVIVAL;

EID: 26644458103     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.10.006     Document Type: Article

References (33)

1. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators N. Engl. J. Med. 325 1991 293 302
2. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez The effect of spironolactone on morbidity and mortality in patients with severe heart failure N. Engl. J. Med. 341 1999 709 717
3. CIBIS-II investigators and committees The cardiac insufficiency bisoprolol study: II (CIBIS-II). A randomised trial Lancet 353 1999 9 13
4. MERIT-HF study group Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF) Lancet 353 1999 2001 2007
5. M. Packer, A.J. Coats, M.B. Fowler, H.A. Katus, H. Krum, and P. Mohacsi Effect of carvedilol on survival in severe chronic heart failure N. Engl. J. Med. 344 2001 1651 1658
6. J.N. Cohn, G.R. Johnson, R. Shabetai, H. Loeb, F. Tristani, and T. Rector Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA cooperative studies group Circulation 87 1993 VI5 VI6
7. D.M. Mancini, H. Eisen, W. Kussmaul, R. Mull, L.H. Edmunds Jr., and J.R. Wilson Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure Circulation 83 1991 778 786
8. A.M. Stelken, L.T. Younis, S.H. Jennison, D.D. Miller, L.W. Miller, and L.J. Shaw Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy J. Am. Coll. Cardiol. 27 1996 345 352
9. P. de Groote, A. Millaire, C. Foucher-Hossein, O. Nugue, X. Marchandise, and G. Ducloux Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure J. Am. Coll. Cardiol. 32 1998 948 954
10. P. de Groote, J. Dagorn, B. Soudan, N. Lamblin, E. Mc Fadden, and C. Bauters B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure J. Am. Coll. Cardiol. 43 2004 1584 1589
11. B. Andersson, and C. Sylven The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure J. Am. Coll. Cardiol. 28 1996 162 167
12. V. Vancura, J. Hubacek, I. Malek, M. Gebauerova, J. Pitha, and Z. Dorazilova Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy? Am. J. Cardiol. 83 1999 461 462
13. M. Börjesson, Y. Magnusson, A. Hjalmarson, and B. Andersson A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure Eur. Heart J. 21 2000 1853 1858
14. S.B. Liggett, L.E. Wagoner, L.L. Craft, R.W. Hornung, B.D. Hoit, and T.C. McIntosh The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure J. Clin. Invest. 102 1998 1534 1539
15. H.L. White, R.A. de Boer On behalf of the MERIT-HF Study Group An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF substudy Eur. J. Heart Fail. 5 2003 463 468
16. D.A. Rathz, K.M. Brown, L.A. Kramer, and S.B. Ligett Amino acid 49 polymorphisms of the human beta 1-adrenergic receptor affect agonist-promoted trafficking J. Cardiovasc. Pharmacol. 39 2002 155 160
17. S. Green, J. Turki, M. Innis, and S.B. Ligett Amino-terminal polymorphisms of the β2-adrenergic receptor impart distinct agonist-promoted regulatory properties Biochemistry 33 1994 9414 9419
18. 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation J. Biol. Chem. 277 2002 30429 30435
19. V. Dishy, G.G. Sofowora, H.G. Xie, R.B. Kim, D.W. Byrne, and M. Stein The effect of common polymorphisms of the β2-adrenergic receptor on agonist-mediated vascular desensitization N. Engl. J. Med. 345 2001 1030 1035
20. D.A. Mason, J.D. Moore, S.A. Green, and S.B. Liggett A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor J. Biol. Chem. 274 1999 12670 12674
21. S.A. Green, G. Cole, M. Jacinto, M. Innis, and S.B. Liggett A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor J. Biol. Chem. 268 1993 23116 23121
22. J. Turki, J.N. Lorenz, S.A. Green, E.T. Donnelly, M. Jacinto, and S.B. Liggett Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice Proc. Natl. Acad. Sci. U. S. A. 93 1996 10483 10488
23. S.A. Miller, D.D. Dykes, and H.F. Polesky A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res. 16 1988 1215
24. A. Maqbool, A.S. Hall, S.G. Ball, and A.J. Balmforth Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay Lancet 353 1999 897
25. V. Large, L. Hellstrom, S. Reynisdottir, F. Lonnqvist, P. Eriksson, and L. Lannfelt Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function J. Clin. Invest. 100 1997 3005 3013
26. A. Meirhaeghe, N. Helbecque, D. Cottel, and P. Amouyel Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population Int. J. Obes. Relat. Metab. Disord. 24 2000 382 387
27. L. Excoffier, and M. Slatkin Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population Mol. Biol. Evol. 12 1995 921 927
28. M. Stephens, N.J. Smith, and P. Donnelly A new statistical method for haplotype reconstruction from population data Am. J. Hum. Genet. 68 2001 978 989
29. J.H. Zhao, S. Lissarrague, L. Essioux, and P.C. Sham GENOCOUNTING: haplotype analysis with missing genotypes Bioinformatics 18 2002 1694 1695
30. 1-adrenoceptor does not influence blood pressure or heart rate response to b-blockade in hypertensive subjects Clin. Sci. 99 2000 233 238
31. O.E. Brodde, R. Büscher, R. Tellkamp, J. Radke, S. Dhein, and P.A. Insel Blunted cardiac responses to receptor activation in subjects withThr164Ile β2-adrenoceptors Circulation 103 2001 1048 1050
32. 2-adrenergic receptor down-regulation Clin. Pharmacol. Ther. 74 2002 255 263
33. 2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional response in vivo Pharmacogenetics 13 2002 59 66